Oversubscribed Novo Nordisk takes increase after only one decline
Only one invited bank declined to participate in a €650m five year revolver for Danish pharmaceutical firm Novo Nordisk.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
